Zobrazeno 1 - 5
of 5
pro vyhledávání: '"van den Handel, Kim"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Years of important research has revealed that cells heavily invest in regulating their size. Nevertheless, it has remained unclear why accurate size control is so important. Our recent study using hematopoietic stem cells (HSCs) in vivo indicates tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1593::97b7196dcf6b7d02cab929f8108b9e4d
http://hdl.handle.net/10138/351876
http://hdl.handle.net/10138/351876
Autor:
Keller, Kaylee M., Eleveld, Thomas F., Schild, Linda, van den Handel, Kim, van den Boogaard, Marlinde, Amo-Addae, Vicky, Eising, Selma, Ober, Kimberley, Koopmans, Bianca, Looijenga, Leendert, Tytgat, Godelieve A.M., Ylstra, Bauke, Molenaar, Jan J., Dolman, M. Emmy M., van Hooff, Sander R., Afd Pharmaceutics, Pharmaceutics
Publikováno v:
Frontiers in Oncology, 12, 1. Frontiers Media S.A.
Frontiers in Oncology, 12:929123. Frontiers Media S.A.
Frontiers in oncology, 12:929123. Frontiers Media S.A.
Keller, K M, Eleveld, T F, Schild, L, van den Handel, K, van den Boogaard, M, Amo-Addae, V, Eising, S, Ober, K, Koopmans, B, Looijenga, L, Tytgat, G A M, Ylstra, B, Molenaar, J J, Dolman, M E M & van Hooff, S R 2022, ' Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma ', Frontiers in Oncology, vol. 12, 929123 . https://doi.org/10.3389/fonc.2022.929123
Frontiers in Oncology, 12:929123. Frontiers Media S.A.
Frontiers in oncology, 12:929123. Frontiers Media S.A.
Keller, K M, Eleveld, T F, Schild, L, van den Handel, K, van den Boogaard, M, Amo-Addae, V, Eising, S, Ober, K, Koopmans, B, Looijenga, L, Tytgat, G A M, Ylstra, B, Molenaar, J J, Dolman, M E M & van Hooff, S R 2022, ' Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma ', Frontiers in Oncology, vol. 12, 929123 . https://doi.org/10.3389/fonc.2022.929123
Neuroblastoma is the most common extracranial solid tumor found in children and despite intense multi-modal therapeutic approaches, low overall survival rates of high-risk patients persist. Tumors with heterozygous loss of chromosome 11q and MYCN amp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::329aea7d7c7654768bccaddc20ad5c25
https://dspace.library.uu.nl/handle/1874/425877
https://dspace.library.uu.nl/handle/1874/425877
Autor:
Davies DM; Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland., van den Handel K; Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland., Bharadwaj S; Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland., Lengefeld J; Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Publikováno v:
Frontiers in cell and developmental biology [Front Cell Dev Biol] 2022 Nov 10; Vol. 10, pp. 1036602. Date of Electronic Publication: 2022 Nov 10 (Print Publication: 2022).
Autor:
Keller KM; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Eleveld TF; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Schild L; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., van den Handel K; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., van den Boogaard M; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Amo-Addae V; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Eising S; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Ober K; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Koopmans B; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Looijenga L; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Tytgat GAM; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Ylstra B; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands., Molenaar JJ; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Pharmaceutical Sciences, University Utrecht, Utrecht, Netherlands., Dolman MEM; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Children's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, Australia.; School of Women's and Children's Health, Faculty of Medicine, UNSW Sydney, Kensington, NSW, Australia., van Hooff SR; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Publikováno v:
Frontiers in oncology [Front Oncol] 2022 Sep 27; Vol. 12, pp. 929123. Date of Electronic Publication: 2022 Sep 27 (Print Publication: 2022).